Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00919217 · ClinicalTrials.gov registry record
Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms
A clinical trial of Relapsing Remitting Multiple Sclerosis, sponsored by University of Louisville.
- Recruiting
- Registry status
- 80
- Enrollment target
- 1
- Study location
NCT00919217: Recruiting study of Relapsing Remitting Multiple Sclerosis, sponsored by University of Louisville.
NCT00919217 is a study of Relapsing Remitting Multiple Sclerosis that is actively recruiting participants, run by University of Louisville. The registered enrollment target is 80 participants, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00919217, a study of Relapsing Remitting Multiple Sclerosis, is actively recruiting participants, sponsored by University of Louisville.
- RECRUITING
- Registry status
- 80 participants
- Enrollment target
- 1
- Study location
Study Summary
The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
Conditions Studied
Study Locations (1)
Kentucky
- University of Louisville (recruiting nationwide) - Louisville
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 80 participants |
| Start Date | 2008-08 |
| Est. Completion | 2025-12 |
What NCT00919217 shows while recruiting
NCT00919217 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 80 participants, a relatively small participant target, below the 199-participant average among 25 other Relapsing Remitting Multiple Sclerosis trials with a reported enrollment target (60% lower).
The record links to 1 condition, with Relapsing Remitting Multiple Sclerosis appearing as the primary indexed condition, and to 0 interventions.
NCT00919217 reports a single indexed study location in Kentucky.
Frequently Asked Questions
What is clinical trial NCT00919217 about?
NCT00919217 is a clinical study titled "Exploratory Study on the Timing of Multiple Sclerosis (MS) Symptoms". The investigators' overall hypothesis is that appearance or worsening of relapsing-remitting multiple sclerosis (RR-MS) symptoms are affected by various factors including stress, hormonal cycles, illness and missed medications.
What is the current status of trial NCT00919217?
This trial is currently recruiting. The enrollment target is 80 participants. The study started on 2008-08. Estimated completion is 2025-12.
What conditions does trial NCT00919217 study?
This clinical trial studies the following conditions: Relapsing Remitting Multiple Sclerosis.
Who is sponsoring clinical trial NCT00919217?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00919217 being conducted?
This trial has 1 study location across Kentucky. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Relapsing Remitting Multiple Sclerosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00919217's enrollment target sits among peer trials
80 13th of 25 higher than 12 of 25 other Relapsing Remitting Multiple Sclerosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Relapsing Remitting Multiple Sclerosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Study to Evaluate the Usability and Value of Integrated Digital Solutions in Medical Care of Participants With Multiple Sclerosis
RECRUITING
-
The SetPoint System as a Pro-Remyelination Therapy for Relapsing-Remitting Multiple Sclerosis: A Pilot Study
RECRUITING · NA
-
Functional Outcomes From Diets in Multiple Sclerosis
RECRUITING · NA
-
Best Available Therapy Versus Autologous Hematopoietic Stem Cell Transplant for Multiple Sclerosis (BEAT-MS)
RECRUITING · Phase 3
-
Clinically Isolated Syndrome and Relapsing-Remitting Multiple Sclerosis
ACTIVE NOT RECRUITING · NA
-
Reduced Oligodendrocyte-specific Cytotoxicity and Ofatumumab Treatment
ACTIVE NOT RECRUITING
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01243931 · 80 participants · NA
Optical Coherence Tomography Guided Transepithelial Phototherapeutic Keratectomy
- NCT01659203 · 80 participants · Phase 1
Proton or Photon RT for Retroperitoneal Sarcomas
- NCT01803451 · 80 participants · Early Phase 1
Glucagon-like Peptide 1, Glucose Metabolism and Gastric Bypass
- NCT01964859 · 80 participants · Phase 2
Feasibility Study for Fibroblast Autologous Skin Grafts
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia